Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7077-7087

  Mittal, Anupama ^a   Chitkara, Deepak ^a   Behrman, Stephan W ^b   Mahato, Ram I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer; Gemcitabine; Micelles; MiR 205; MiRNA; Pancreas

Indexed keywords

CELL DEATH; CELL PROLIFERATION; DISEASES; DRUG PRODUCTS; MICELLES; STEM CELLS; TUMORS;

CANCER; GEMCITABINE; MIR-205; MIRNA; PANCREAS;

RNA;

COPOLYMER; GEMCITABINE; LIPOFECTAMINE; LIPOPLEX; MICRORNA 205; MIRVANA; UNCLASSIFIED DRUG; DEOXYCYTIDINE; LIGAND; MACROGOL DERIVATIVE; MICELLE; MICRORNA; MIRN205 MICRORNA, HUMAN; POLYMER;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG STABILITY; GENE EXPRESSION; GENETIC TRANSFECTION; HYDRATION; IMMUNOHISTOCHEMISTRY; LIPOSOMAL DELIVERY; MICELLE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RING OPENING; SUSTAINED DRUG RELEASE; TUMOR GROWTH; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HUMAN; MALE; NUDE MOUSE; PANCREATIC NEOPLASMS; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

AGOUTI PACA; ANIMALIA;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MICE, NUDE; MICELLES; MICRORNAS; PANCREATIC NEOPLASMS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYMERS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902076605     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.053     Document Type: Article

References (58)

1. Ko A.H., Truong T.G., Kantoff E., Jones K.A., Dito E., Ong A., et al. Aphase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2012, 70:875-881.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Sultana A., Smith C.T., Cunningham D., Starling N., Neoptolemos J.P., Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. JClin Oncol 2007, 25:2607-2615.
4. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. NEngl J Med 2011, 364:1817-1825.
5. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. JClin Oncol 1997, 15:2403-2413.
6. Vandana M., Sahoo S.K. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 2010, 31:9340-9356.
7. Pasut G., Canal F., Dalla Via L., Arpicco S., Veronese F.M., Schiavon O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. JControl Release 2008, 127:239-248.
8. Graeser R., Bornmann C., Esser N., Ziroli V., Jantscheff P., Unger C., et al. Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas 2009, 38:330-337.
9. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008, 68:918-926.
10. Berlin J.D., Adak S., Vaughn D.J., Flinker D., Blaszkowsky L., Harris J.E., et al. Aphase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an eastern cooperative oncology group study (E3296). Oncology 2000, 58:215-218.
11. Rocha Lima C.M., Savarese D., Bruckner H., Dudek A., Eckardt J., Hainsworth J., et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. JClin Oncol 2002, 20:1182-1191.
12. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: eastern cooperative oncology group trial E2297. JClin Oncol 2002, 20:3270-3275.
13. Rocha Lima C.M., Green M.R., Rotche R., Miller W.H., Jeffery G.M., Cisar L.A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. JClin Oncol 2004, 22:3776-3783.
14. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. NEngl J Med 2013, 369:1691-1703.
15. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008, 14:5995-6004.
16. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. JCell Biochem 2007, 101:887-907.
17. Chitkara D., Mittal A., Behrman S.W., Kumar N., Mahato R.I. Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma. Bioconjug Chem 2013, 24:1161-1173.
18. Singh S., Chitkara D., Kumar V., Behrman S.W., Mahato R.I. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013, 334:211-220.
19. Izumiya M., Kabashima A., Higuchi H., Igarashi T., Sakai G., Iizuka H., et al. Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res 2012, 32:3847-3853.
20. Singh S., Chitkara D., Mehrazin R., Behrman S.W., Wake R.W., Mahato R.I. Chemoresistance in prostate cancer cells is regulated by miRNAs and hedgehog pathway. PLoS One 2012, 7:e40021.
21. Lu Y., Zhu H., Shan H., Lu J., Chang X., Li X., et al. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett 2013, 340:113-123.
22. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA invivo. FEBS J 2010, 277:4814-4827.
23. Guidry E.N., Farand J., Soheili A., Parish C.A., Kevin N.J., Pipik B., et al. Improving the invivo therapeutic index of siRNA polymer conjugates through increasing pH responsiveness. Bioconjug Chem 2014, 25:296-307.
24. Braun G.B., Pallaoro A., Wu G., Missirlis D., Zasadzinski J.A., Tirrell M., et al. Laser-activated gene silencing via gold nanoshell-siRNA conjugates. ACS Nano 2009, 3:2007-2015.
25. Gao L.Y., Liu X.Y., Chen C.J., Wang J.C., Feng Q., Yu M.Z., et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for invivo siRNA delivery. Biomaterials 2014, 35:2066-2078.
26. Nelson C.E., Kintzing J.R., Hanna A., Shannon J.M., Gupta M.K., Duvall C.L. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity invivo. ACS Nano 2013, 7:8870-8880.
27. Patil S.P., Jeong H.S., Kim B.H. Alow-molecular-weight supramolecular hydrogel of riboflavin bolaamphiphile for VEGF-siRNA delivery. Chem Commun (Camb) 2012, 48:8901-8903.
28. Kim Y.M., Park M.R., Song S.C. Injectable polyplex hydrogel for localized and long-term delivery of siRNA. ACS Nano 2012, 6:5757-5766.
29. Sato Y., Hatakeyama H., Sakurai Y., Hyodo M., Akita H., Harashima H. ApH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity invitro and invivo. JControl Release 2012, 163:267-276.
30. Ozpolat B., Sood A.K., Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 2014, 66:110-116.
31. Danquah M., Fujiwara T., Mahato R.I. Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials 2010, 31:2358-2370.
32. Paraskevopoulou M.D., Vlachos I.S., Athanasiadis E., Spyrou G. BiDaS: a web-based Monte Carlo BioData Simulator based on sequence/feature characteristics. Nucleic Acids Res 2013, 41:W582-W586.
33. Reczko M., Maragkakis M., Alexiou P., Grosse I., Hatzigeorgiou A.G. Functional microRNA targets in protein coding sequences. Bioinformatics 2012, 28:771-776.
34. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
35. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27:91-105.
36. Garcia D.M., Baek D., Shin C., Bell G.W., Grimson A., Bartel D.P. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 2011, 18:1139-1146.
37. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
38. Vergoulis T.I., Vlachos P., Alexiou G., Georgakilas M., Maragkakis M., Reczko S., et al. Capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res 2012, 40(D1):D222-D229. Tarbase 6.0.
39. Chitkara D., Singh S., Kumar V., Danquah M., Behrman S.W., Kumar N., et al. Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Mol Pharm 2012, 9:2350-2357.
40. Bhatnagar N., Li X., Padi S.K., Zhang Q., Tang M.S., Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010, 1:e105.
41. Boll K., Reiche K., Kasack K., Morbt N., Kretzschmar A.K., Tomm J.M., et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013, 32:277-285.
42. Tellez C.S., Juri D.E., Do K., Bernauer A.M., Thomas C.L., Damiani L.A., et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011, 71:3087-3097.
43. Adachi R., Horiuchi S., Sakurazawa Y., Hasegawa T., Sato K., Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun 2011, 411:804-808.
44. Lee J.Y., Park M.K., Park J.H., Lee H.J., Shin D.H., Kang Y., et al. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 2013, 33:1325-1335.
45. Dar A.A., Majid S., de Semir D., Nosrati M., Bezrookove V., Kashani-Sabet M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. JBiol Chem 2011, 286:16606-16614.
46. Matsushima K., Isomoto H., Yamaguchi N., Inoue N., Machida H., Nakayama T., et al. miRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. JTransl Med 2011, 9:30.
47. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
48. Song H., Bu G. MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1. Biochem Biophys Res Commun 2009, 388:400-405.
49. Gandellini P., Profumo V., Casamichele A., Fenderico N., Borrelli S., Petrovich G., et al. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ 2012, 19:1750-1760.
50. Wang N., Li Q., Feng N.H., Cheng G., Guan Z.L., Wang Y., et al. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J Androl 2013, 15:735-741.
51. Arote R., Kim T.H., Kim Y.K., Hwang S.K., Jiang H.L., Song H.H., et al. Abiodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier. Biomaterials 2007, 28:735-744.
52. Ogris M., Brunner S., Schuller S., Kircheis R., Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 1999, 6:595-605.
53. Xiong X.B., Uludag H., Lavasanifar A. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 2009, 30:242-253.
54. Salem A.F., Bonuccelli G., Bevilacqua G., Arafat H., Pestell R.G., Sotgia F., et al. Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle 2011, 10:3692-3700.
55. Huang C., Qiu Z., Wang L., Peng Z., Jia Z., Logsdon C.D., et al. Anovel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res 2012, 72:655-665.
56. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011, 19:1116-1122.
57. Wu Y., Crawford M., Mao Y., Lee R.J., Davis I.C., Elton T.S., et al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol Ther Nucleic Acids 2013, 2:e84.
58. Torrisani J., Bournet B., du Rieu M.C., Bouisson M., Souque A., Escourrou J., et al. Let-7 microRNA transfer in pancreatic cancer-derived cells inhibits invitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009, 20:831-844.